Instrument Inactif

Communiqués IDERA PHARMACEUTIC NYSE

Actions

IDRA

US45168K3068

Cours en clôture NYSE Autres places de cotation
- ^USD	-

Communiqués

30/11/-1	Idera Pharma : Idera Pharmaceuticals to Participate at BIO InvestorForum 2007	BU
30/11/-1	Idera Pharma : Idera Pharmaceuticals Announces the Appointment of Hans Mueller, Ph.D., to Its Board of Directors	BU
30/11/-1	Idera Pharma : Idera Pharmaceuticals Presents Preclinical Data on IMO-2125 and Other TLR9 Agonists	BU
30/11/-1	Idera Pharma : Idera Pharmaceuticals Initiates Phase 1 Trial of IMO-2125 in Hepatitis C	BU
30/11/-1	Idera Pharma : Idera Pharmaceuticals to Participate in Upcoming Conferences	BU
30/11/-1	Idera Pharma : Idera Pharmaceuticals Presents Interim Data from Phase 1 Study Evaluating IMO-2055 in Combination with Gemcitabine and Carboplatin	BU
30/11/-1	Idera Pharma : Idera Pharmaceuticals Announces Issuance of US Patent for Novel Immunostimulatory Oligonucleotide Compositions	BU
30/11/-1	Idera Pharma : Idera Pharmaceuticals Announces Publication of Preclinical Data on Toll-Like Receptor 7 and 8 Agonists	BU
30/11/-1	Idera Pharma : Idera Pharmaceuticals to Present at Canaccord Adams 27th Annual Global Growth Conference	BU
30/11/-1	Idera Pharma : Idera Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2007	BU
30/11/-1	Idera Pharma : Idera Pharmaceuticals Announces Publication of Study of Toll-Like Receptor 9 Agonist in Combination with Avastin(R) in Preclinical Colon Cancer Model	BU
30/11/-1	Idera Pharma : Idera Pharmaceuticals Presents Preclinical Data of Toll-Like Receptor Antagonists in Rheumatoid Arthritis Models	BU
30/11/-1	Idera Pharma : Idera Pharmaceuticals Announces Chief Financial Officer to Leave Company Effective July 31, 2007	BU
30/11/-1	Idera Pharma : Idera Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2007	BU
30/11/-1	Idera Pharma : Idera Pharmaceuticals to Present at Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference	BU
30/11/-1	Idera Pharma : Idera Pharmaceuticals to Present at BIO Business Forum and Participate in Toll-Like Receptor Panel at BIO 2007	BU
30/11/-1	Idera Pharma : Idera Pharmaceuticals Announces Presentations of Preclinical Data on New Potential Oncology Applications of its TLR9 Agonists at AACR	BU
30/11/-1	Idera Pharma : Idera Pharmaceuticals to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference	BU
30/11/-1	Idera Pharma : Idera Pharmaceuticals Announces 2006 Financial Results for the Three and Six Months Ended June 30, 2006; Recent Highlights Include Expanded TLR Programs and Additional Funding	BU
30/11/-1	Idera Pharma : Idera Pharmaceuticals Announces the Issuance of US Patent Claiming Compounds that Target Toll-like Receptor 9	BU
30/11/-1	Idera Pharma : Idera Pharmaceuticals to Present at Upcoming Investor Conferences	BU
30/11/-1	Idera Pharma : Idera to Draw Down $4 Million under Existing Equity Vehicle	BU
30/11/-1	Idera Pharma : Idera Pharmaceuticals Announces Issuance of a US Patent for Method of Inducing an Immune Response through Administration of Immune Modulatory Oligonucleotides	BU
30/11/-1	Idera Pharma : Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2006 Financial Results	BU
30/11/-1	Idera Pharma : Idera Pharmaceuticals Announces Extension of Research Collaboration on Asthma and Allergy	BU